AN2 Therapeutics, Inc.

NASDAQ:ANTX

Biotechnology

Healthcare
$4.95 +0.82%

+$0.04 today

Market cap
$187.82M
Beta
-0.98
P/E (TTM)
-4.9
EPS (TTM)
-$1.01
52W Low $1.00High $6.91

Volume 0.97M

Average 0.29M

ANTX Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

No reported Net Margin figures are available to summarize.

Net Margin history

Percent of revenue · from the income statement

No Net Margin data reported for this period type.

Net Margin vs competitors

How ANTX compares with its peers on the latest reported figures

ANTX Competitors Peer median
Net Margin for ANTX and competitors
Company Period LTM level YoY 3-year change
QTTBQ32 Bio Inc.LTM Mar 202661.9% —+699.1 pp
VRCAVerrica Pharmaceuticals Inc.LTM Mar 2026-48.0% +871.2 pp+220.8 pp
IBIOiBio, Inc.LTM Jun 2026-33044.0% -28449.8 pp—
ANTXAN2 Therapeutics, Inc.FY2025— ——
SABSSAB Biotherapeutics, Inc.FY2025— ——
BOLDBoundless Bio, Inc.FY2025— ——
Peer median (excluding ANTX) -48.0%-13789.3 pp+460.0 pp

Competitors are the stored peer set for ANTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue077K000
Gross Profit0(77K)000
Gross Margin—————
Research & Development16.91M29.51M54.87M40.49M24.77M
Selling, General & Admin4.67M12.75M14.76M14.07M13.34M
Operating Expenses21.57M42.19M69.64M54.55M38.11M
Depreciation & Amortization077K69.64M54.55M0
EBITDA(21.54M)(40.88M)4.9M3.23M(35.17M)
EBITDA Margin—————
Operating Income(21.57M)(42.26M)(69.64M)(54.55M)(38.11M)
Operating Margin—————
Interest Income69K1.35M4.86M5.47M2.93M
Interest Expense0514K000
Other Income / Expenses31K1.31M4.9M3.23M2.94M
Income Before Tax(21.54M)(40.96M)(64.73M)(51.32M)(35.17M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(21.54M)(40.96M)(64.73M)(51.32M)(35.17M)
Net Margin—————
EPS (Basic)(1.50)(2.79)(2.74)(1.72)(1.16)
EPS (Diluted)(1.50)(2.79)(2.74)(1.72)(1.16)
Weighted Avg Shares18.74M15.34M23.6M29.83M30.22M
Weighted Avg Shares (Diluted)18.74M15.34M23.6M29.83M30.22M

AN2 Therapeutics, Inc.

NASDAQ:ANTX

Intrinsic Alpha fair value

Locked

Current Price

$4.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.